RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy
Abstract:
RNA interference (RNAi) entails the potential for novel therapeutic strategies through the silencing of disease-causing genes in vivo. However, recent studies have raised an issue regarding applicable routes of administration for small interfering RNA (siRNA) molecules as therapeutics. In this study, we demonstrate that liposomally formulated siRNA molecules, the so-called siRNA-lipoplexes, but not naked siRNAs, are delivered to the tumor endothelial cells in vivo by microscopy. In addition, functional intracellular delivery of formulated siRNA targeting the tumor suppressor PTEN is shown in endothelial cells of the liver and tumor. Finally, the therapeutic potential of systemically administered siRNA(CD31)-lipoplexes is established by inhibition of tumor growth in two different xenograft mouse models. Our findings corroborate the applicability of this liposomal siRNA delivery technology for inducing RNAi to modulate gene expression levels in angiogenesis-dependent processes. In addition, our results advocate CD31 as a promising therapeutic target for antiangiogenic intervention. Therefore, our study provides a basis for the development of antiangiogenic cancer therapies based on RNAi.
Insights
Liposomal delivery of small interfering RNA (siRNA) effectively targets tumor endothelial cells, enabling gene silencing for potential anti-cancer therapies. This liposomal siRNA technology shows promise for inhibiting tumor growth by modulating angiogenesis.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- RNA interference (RNAi) offers therapeutic potential for silencing disease-causing genes.
- Effective in vivo delivery of small interfering RNA (siRNA) molecules remains a challenge for therapeutic applications.
Purpose of the Study:
- To investigate the efficacy of liposomal siRNA formulations for targeted delivery and gene silencing in tumor endothelial cells.
- To evaluate the therapeutic potential of siRNA targeting CD31 for anti-angiogenic cancer therapy.
Main Methods:
- Microscopic visualization of siRNA-lipoplex delivery to tumor endothelial cells in vivo.
- Assessment of functional intracellular delivery of siRNA targeting PTEN in liver and tumor endothelial cells.
- Evaluation of tumor growth inhibition using systemically administered siRNA(CD31)-lipoplexes in xenograft mouse models.
Main Results:
- Liposomally formulated siRNA (siRNA-lipoplexes) demonstrated effective delivery to tumor endothelial cells, unlike naked siRNAs.
- Functional intracellular delivery of siRNA targeting PTEN was confirmed in liver and tumor endothelial cells.
- Systemic administration of siRNA(CD31)-lipoplexes significantly inhibited tumor growth in two xenograft models.
Conclusions:
- Liposomal siRNA delivery technology is applicable for RNAi-mediated gene modulation in angiogenesis-dependent processes.
- CD31 is identified as a promising therapeutic target for anti-angiogenic interventions.
- The study provides a foundation for developing RNAi-based anti-angiogenic cancer therapies.
Related Concept Videos
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:22MicroRNAs